Lyophilization News and Research

RSS

Freeze-drying, also referred to as lyophilization, is a process that involves freezing a substance at very low temperatures and then extracting liquid via sublimation, converting water from a solid to gaseous state.

Soligenix reports positive results from preclinical studies of vaccine thermostabilization technology

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

6 Feb 2012

Low temperature vacuum drying process for production of probiotics

Probiotic bacteria are rapidly gaining ground as healthy food supplements. However, the production of this "functional food" has its pitfalls: only few probiotic bacterial strains are robust enough to survive conventional production processes.

7 Jul 2011

ETI finalizes proprietary progesterone formulations for Traumatic Brain Injury

Encore Therapeutics, Inc. today reported finalizing its proprietary phospholipid nanoemulsion formulation of progesterone.

12 May 2011

BioSpecifics 2010 net loss decreases to $1.5 million

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended December 31, 2010.

11 Mar 2011

Combined diagnosis and treatment of tumors: photothermically activated ultrasound contrast agent

Diagnosis and treatment form the basis of modern medicine. Traditionally, they are two separate steps; however, it doesn’t have to be that way. The term “theranostic” refers to the combination of a diagnostic test with a specific treatment based on the result of the test. This integrated approach should be particularly helpful in providing more targeted treatment for cancer patients.

1 Mar 2011

TriLink signs licensing agreement to use CleanAmp dNTPs in Biofortuna's PCR kits

TriLink BioTechnologies, Inc. announced that it has signed a licensing agreement with Biofortuna Ltd. (Biofortuna) for use of CleanAmp dNTPs in Biofortuna's freeze dried in vitro diagnostic PCR kits.

15 Sep 2010

Advaxis, Vibalogics to develop storage-stable formulation for live Listeria vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company and Vibalogics GmbH, a German biologics manufacturing company, have agreed to co-develop a room temperature stable, processing technology for live vaccines originally engineered for Advaxis.

12 Aug 2010

LLC to provide contract drug development services

LyoTechnica, LLC has announced that it has been established to provide contract drug development services for injectable pharmaceuticals. The company and its affiliates bring over 80 years of combined experience in lyophilization and liquid dosage form development as well as over 100 years experience in commercial scale manufacturing of parenteral drugs. The company offers analytical and formulation development, manufacturing of sterile stability batches and stability testing services.

16 Jul 2010

Cepheid denies Abaxis' allegations of patent infringement, files answer and counterclaims

Cepheid announced today that it has filed an answer and counterclaims in a patent suit brought by Abaxis on June 28, 2010 in the United States District Court for the Northern District of California. In its filing, Cepheid denied Abaxis' allegations of patent infringement, asked the Court to determine it has paid all royalties due and is in full compliance with all the terms of its license, and to find that Abaxis' patents are invalid.

13 Jul 2010

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

15 Jun 2010

Scientists make water-free liquid from blood protein

Scientists at the University of Bristol have discovered a way to make a highly concentrated water-free liquid of a key blood protein, myoglobin, opening up the possibility of new types of biomedical materials.

6 Jun 2010

Osprey Biomedical rolls out Eagle Cervical Allograft Series in ATPS Preservation System

Osprey Biomedical, a global spinal allograft bio-implant company announced today it has begun the roll out of its Eagle Cervical Allograft Series being offered in its ATPS Preservation System.

28 May 2010

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.

22 Apr 2010

Patheon's first-quarter fiscal 2010 total revenues up 5.2%

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry today announced results for its first quarter ended January 31, 2010. All amounts are in U.S. dollars unless otherwise indicated.

15 Mar 2010

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

New data from PharmAthene's anthrax vaccine program presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C.

5 Dec 2009

Formatech launches new website

Formatech, Inc is pleased to announce the launch of their new website. The redesigned site features detailed information about the variety of services Formatech offers, including: product development, lyophilization development, their signature Stability Fingerprinting® program and cGMP manufacturing capabilities to support clinical trials, to name a few. The site also provides the latest Formatech news, events, case studies and offers detailed information on their recently established Fillanthropy™ Program.

20 Nov 2009

Althea Technologies offers formulation development services

Althea Technologies, Inc., a leading provider of development and manufacturing services for biopharmaceutical products announced the addition of customized Formulation Development to the company's platform of services, which will be overseen by the newly appointed Dr. James Matsuura, Director of Formulation Development.

5 Nov 2009

EnWave receives R&D funding to develop REV dehydration technologies

EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") today announced that it has received research and development funding from three separate Canadian federal and provincial government agencies totaling $370,000 to continue the Company's development of its Radiant Energy Vacuum ("REV") dehydration technology for food, food cultures, and biopharmaceuticals.

30 Sep 2009

Three antibodies dried using EnWave's freezeREV vial dehydration technology

EnWave Corporation ("EnWave" or "the Company") today announced that it has successfully dried three different antibodies in the Company's prototype freezeREV vial dehydration technology.

25 Sep 2009